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G-protein-coupled receptors function as oligomers in vivo
Mark C. Overton and Kendall J. Blumer
Hormones, sensory stimuli, neurotransmitters and
chemokines signal by activating G-protein-coupled
receptors (GPCRs) [1]. Although GPCRs are thought to
function as monomers, they can form SDS-resistant
dimers, and coexpression of two non-functional or
related GPCRs can result in rescue of activity or
modification of function [2–10]. Furthermore,
dimerization of peptides corresponding to the third
cytoplasmic loops of GPCRs increases their potency as
activators of G proteins in vitro [11], and peptide
inhibitors of dimerization diminish β2-adrenergic receptor
signaling [3]. Nevertheless, it is not known whether
GPCRs exist as monomers or oligomers in intact cells
and membranes, whether agonist binding regulates
monomer–oligomer equilibrium, or whether
oligomerization governs GPCR function. Here, we report
that the α-factor receptor, a GPCR that is the product of
the STE2 gene in the yeast Saccharomyces cerevisiae, is
oligomeric in intact cells and membranes. Coexpression
of receptors tagged with the cyan or yellow fluorescent
proteins (CFP or YFP) resulted in efficient fluorescence
resonance energy transfer (FRET) due to stable
association rather than collisional interaction.
Monomer–oligomer equilibrium was unaffected by
binding of agonist, antagonist, or G protein
heterotrimers. Oligomerization was further demonstrated
by rescuing endocytosis-defective receptors with
coexpressed wild-type receptors. Dominant-interfering
receptor mutants inhibited signaling by interacting with
wild-type receptors rather than by sequestering G
protein heterotrimers. We suggest that oligomerization
is likely to govern GPCR signaling and regulation.
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Results and discussion
To determine whether the α-factor receptor is an oligomer
in vivo, we performed FRET experiments in conjunction
with cell biological and genetic studies. FRET experi-
ments were performed using cells expressing wild-type
levels of truncated α-factor receptors lacking their cytoplas-
mic carboxy-terminal regulatory domains (Ste2∆tail–CFP,
donor; Ste2∆tail–YFP, acceptor). Tagging truncated recep-
tors with the green fluorescent protein (GFP) does not alter
the cell-surface expression, agonist-binding affinity, signal-
ing efficiency or internalization defect of the mutant recep-
tor [12]. FRET was detected between Ste2∆tail–CFP and
Ste2∆tail–YFP coexpressed at wild-type levels (Figure 1a).
In contrast, FRET was not detected between CFP- and
YFP-tagged full-length receptors (data not shown), indicat-
ing a dependence on interfluorophore distance, orientation
or mobility.
Several results indicated that FRET was due to a direct,
specific, homophilic interaction between tailless receptors,
and not to dimerization through CFP and YFP, non-spe-
cific collisional interaction, or an indirect interaction medi-
ated by the cortical actin cytoskeleton. First, FRET was
not detected when untagged receptors were overex-
pressed (Figure 1b), even though the tagged receptors
were expressed normally at the cell surface as indicated by
quantitation of CFP and YFP fluorescence and by fluores-
cence microscopy (data not shown). Inhibition of FRET
by untagged receptors was specific because overexpres-
sion of a plasma membrane glucose transporter (Hxt1) at a
similar level did not affect FRET between tagged recep-
tors (Figure 1c). Specific inhibition of FRET by overex-
pressed wild-type receptors also suggested that wild-type
receptors oligomerize. Second, FRET was not detected
between CFP-tagged tailless receptors and YFP-tagged
glucose transporters (Figure 1d), indicating that random
collisional interactions between plasma membrane pro-
teins does not cause FRET. Third, a stable, specific inter-
action between α-factor receptors was indicated by the
high apparent efficiency of FRET (18 ± 1%, n = 7;
Figure 1e). Fourth, FRET was detected when the actin
cytoskeleton was disassembled by treating cells with
latrunculin B (Figure 1f).
The apparent efficiencies of FRET observed with control
cells and cells treated with agonist or antagonist were indis-
tinguishable (18% ± 1, n = 6), as indicated by dose-response
and time-course experiments using sub-saturating to satu-
rating ligand concentrations (Figure 1g and data not shown).
Therefore, stabilization of α-factor receptors in either an
active or inactive conformation was not accompanied by
substantial changes in monomer–oligomer equilibrium.
Energy transfer experiments using human β-adrenergic
receptors have yielded similar results (S. Angers, A. Salah-
pour, E. Joly, S. Hilairet, D. Chelsky, M. Dennis and
M. Bouvier, personal communication). Agonist or antagonist
binding could, however, affect receptor distribution among
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oligomeric states (for example, dimers and tetramers), which
would not necessarily affect FRET efficiency. 
FRET was also observed in experiments using purified
plasma membrane fractions derived from cells coexpressing
Ste2∆tail-CFP and Ste2∆tail-YFP (Figure 1h). This result
allowed us to determine whether monomer–oligomer equi-
librium is affected by the formation of receptor–G protein
ternary complexes, or by the sustained activation and disso-
ciation of G protein subunits from the receptor. The appar-
ent efficiency of FRET (20% ± 2%, n = 11) in plasma
membrane fractions was indistinguishable whether recep-
tors and G proteins were inactive (no agonist or GTPγS;
Figure 1i), had formed ternary complexes (5 µM agonist
without GTPγS; Figure 1i), or were activated and uncou-
pled (5 µM agonist and 50 µM GTPγS; Figure 1i). These
results reinforced the conclusion that monomer–oligomer
equilibrium is unaffected during signaling.
The endocytosis defect of GFP-tagged tailless receptors
could be corrected by coexpressing untagged wild-type
receptors (Figure 2), further demonstrating that α-factor
receptor oligomerization occurs in vivo. In these cells,
agonist-independent endocytosis of GFP-tagged tailless
receptors was indicated by fluorescence labeling of
endosomal vesicles and the large lysosome-like vacuole, as
occurred when cells expressed only full-length GFP-tagged
receptors (Figure 2). Cells coexpressing untagged wild-type
receptors and GFP-tagged tailless receptors also displayed
evidence of agonist-induced receptor internalization, as
indicated by time-dependent decreases in the level of cell-
surface GFP-tagged tailless receptors and increases in the
levels of GFP fluorescence associated with endosomes and
the vacuole (Figure 2). The ability of wild-type receptors to
rescue the endocytosis defect of GFP-tagged tailless recep-
tors was not due to stimulation of bulk internalization of
plasma membrane lipids and proteins, because the
Hxt1–GFP fusion was not internalized when coexpressed
with untagged wild-type receptors either with or without
agonist stimulation (Figure 2). In contrast, tailless GFP-
tagged receptors expressed alone did not undergo basal or
agonist induced endocytosis, as indicated by their persis-
tence at the plasma membrane and their inability to localize
to endosomes or the vacuole (Figure 2). Thus, α-factor
receptors appear to be oligomeric in the absence or presence
of agonist, in accord with results of FRET experiments.
To address whether oligomerization is important for recep-
tor signaling, we identified and characterized a dominant-
interfering mutant of the α-factor receptor. This mutant
was termed M250I because of the amino-acid substitution
it contained in the transmembrane segment VI. In cells
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Figure 1
Use of FRET to detect oligomerization of
α-factor receptors in vivo. Yeast cells
expressed tailless α-factor receptors fused to
CFP or YFP (Ste2–CFP or Ste2–YFP, referred
to as Ste2∆tail–CFP and Ste2∆tail–YFP in the
main text) and/or glucose transporters fused to
YFP (Hxt1–YFP), as indicated. Untagged
α-factor receptors (Ste2) or glucose
transporters (Hxt1) were overexpressed where
indicated. (a–g) Intact cells or (h,i) plasma
membrane fractions were excited at the λmax of
CFP (440 nm), and fluorescence emission
detected by scanning fluorometry.
Fluorescence emission due to FRET was
determined by subtracting the emission
spectrum of cells expressing the CFP fusion
alone, and the emission spectrum of cells
expressing YFP fusion alone, from the emission
spectrum of cells coexpressing CFP and YFP
fusion proteins. In (e), the efficiency of FRET
was determined by dividing the integrated
FRET curve by the integrated emission curve
obtained upon direct excitation of YFP at
490 nm. In (f,g,i), only the FRET emission
curves are shown for experiments performed
under the indicated conditions. All results
shown here are representative of at least six
independent experiments.
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expressing only the mutant receptor from a single-copy
plasmid and its normal promoter on a single-copy plasmid,
agonist-binding affinity was impaired ~10-fold (Kd = 19 nM
versus 2 nM; data not shown) whereas cell-surface expres-
sion was reduced only slightly (4,600 sites per cell versus
6,000–8,000 sites per cell; data not shown). Furthermore, in
these cells agonist potency was impaired nearly 10-fold
(that is, EC50 was higher) relative to wild-type receptor con-
trols, as indicated by dose-response curves for expression of
an agonist-inducible reporter gene (FUS1–lacZ; Figure 3a). 
When overexpressed, the dominant-interfering receptor
could inhibit signaling by interacting with wild-type
receptors, or by sequestering a limiting pool of G protein
heterotrimers. The receptor interaction mechanism of
inhibition was supported by the results of three indepen-
dent experiments. First, signaling efficiency (agonist-
induced FUS1–lacZ reporter expression) was attenuated
to a similar extent when cells expressed only the mutant
receptor at normal levels, and when they coexpressed
wild-type receptors at normal levels and mutant recep-
tors at elevated (10-fold) levels (Figure 3a). This result
suggested that hetero-oligomers containing mutant and
wild-type receptors have reduced activity that is similar
to oligomers consisting only of mutant receptors. Second,
a G protein sequestration mechanism was unlikely
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Figure 2
Oligomerization of α-factor receptors during
endocytosis. Fluorescence microscopy was
used to localize GFP-tagged tailless receptors
coexpressed with untagged wild-type
receptors (∆tail–GFP + WT) or alone
(∆tail–GFP), GFP-tagged glucose
transporters expressed with untagged wild-
type receptors (Hxt1–GFP + WT), and wild-
type receptors tagged with GFP (WT–GFP).
Images were acquired before (0 min) or at the
indicated times after the addition of agonist
(α-factor, 5 µM). Endosomal vesicles (E), the
lysosome-like vacuole (V) and the
endoplasmic reticulum (R) are indicated, as
documented previously [14].
Figure 3
Attenuation of signaling upon overexpression of
a dominant-interfering α-factor receptor mutant.
Responses of cells to α-factor (growth arrest
and gene expression) were used to quantify the
signaling efficiencies. (a) For assays of
FUS1–lacZ expression by β-galactosidase
activity, cells expressed normal levels of either
wild-type α-factor receptors (WT) or the
dominant-interfering mutant receptor (M250I),
or they coexpressed wild-type receptors at
normal levels and the indicated mutant
receptors at elevated levels. (b–j) For growth
arrest assays, cells expressed normal levels of
wild-type α-factor receptors and G protein
subunits (WT; b–d), normal levels of wild-type
α-factor receptors and overexpressed G protein
subunits (WT + Gαβγ; e–g), or normal levels of
a functional α-factor receptor–Gα subunit
fusion (WT–Gα; h–j). Cells also overexpressed
wild-type receptors (WT; b,e,h), a
dominant-interfering mutant receptor
(M250I; c,f,i), or a dominant-interfering mutant
receptor with defective G protein coupling
activity (M250I/L236R; d,g,j). Defects in cell
responsiveness were quantified using various
doses of agonist (α-factor); response to a
single dose of agonist (1.5 nmol) is shown.
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because a dominant-interfering phenotype (attenuation of
agonist-induced growth arrest and/or reporter gene expres-
sion) was still observed when: the ability of the mutant
receptor to interact with G proteins was disrupted (by
introducing the L236R substitution in cis in its third cyto-
plasmic loop which we previously showed does not affect
agonist binding affinity or receptor expression [13];
Figure 3a,d,g,j); G protein α, β and γ subunits were over-
expressed approximately 10–20-fold from a high-copy
plasmid carrying the genes encoding each subunit
expressed from their normal promoters (Figure 3e–g); and
the wild-type receptor was fused to the Gα subunit
(Figure 3h–j). Third, overexpression of mutant receptors
(10-fold from the PGK1 promoter) blocked FRET
between CFP- and YFP-tagged tailless wild-type recep-
tors (data not shown) without affecting expression of
tagged receptors, as indicated by quantitation of CFP and
YFP fluorescence and fluorescence microscopy. There-
fore, we suggest that oligomerization of α-factor receptors
may facilitate signaling.
What might the role of receptor oligomerization in G
protein activation be? Oligomerization might stabilize the
activated receptor so that each receptor subunit can activate
a G protein heterotrimer. An alternative that we currently
favor is that receptor subunits in an oligomer contact differ-
ent subunits of the G protein heterotrimer, possibly provid-
ing an efficient means of tilting Gα away from Gβγ, leading
to GDP release [1,14]. This hypothesis is supported by
indications that the cytoplasmic surface of a rhodopsin
monomer is only about half the size of the rhodopsin-
binding surface of its G protein, transducin [2,15–17]. Fur-
thermore, there is evidence that receptors contact the
carboxyl termini of both the Gα and Gγ subunits [18,19].
Therefore, an agonist-activated receptor dimer or
oligomer may provide a surface that stabilizes the G
protein in a conformation that facilitates GDP release and
allows subsequent GTP binding. Because oligomeriza-
tion may impact several aspects of GPCR function, it
would not be surprising if defects in receptor oligomer-
ization are associated with human disease. Pharmacologi-
cal evidence suggests that schizophrenics may have
reduced levels of D2 dopamine receptor dimers [20].
Therefore, studies of diseases that affect various types of
G protein signaling pathways may further elucidate the
functions of GPCR oligomerization.
Supplementary material
Supplementary material including additional methodological detail and
discussion is available at http://current-biology.com/supmat/sup-
matin.htm.
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